Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen

The value of C2 blood levels

Mariana Ferraresso, Luciana Ghio, Graziella Zacchello, Luisa Murer, Fabrizio Ginevri, Francesco Perfumo, Gian Franco Zanon, Ines Fontana, Alessandro Amore, Alberto Edefonti, Sara Vigano, Massimo Cardillo, Mario Scalamogna

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. The management of cyclosporine therapy in pediatric kidney-transplant recipients is largely based on single center's experience rather than on a univocal pharmacokinetic approach based on therapeutic drug monitoring. A prospective multicenter trial was designed to address the question whether C2 blood level monitoring of cyclosporine microemulsion therapy is feasible in the pediatric setting. Methods. Sixty-four pediatric kidney-transplant recipients receiving a triple immunosuppressive regimen based on cyclosporine microemulsion had their cyclosporine dose adjusted to the same protocol-defined C2 targets from the time of the transplant until 2 years posttransplant. The interim analyses after 1 year of enrolment is presented in this study. Results. One-year patient and graft survival were 100% and 94.8%, respectively. One-year rejection rate was 15%. C2 management of cyclosporine did not affect graft function: 1-year serum creatinine and glomerular filtration rate were 1.3±1 mg/mL and 71.2±20 mL/min/1.73 m2, respectively. C2 was the best single-point predictor of the area under the concentration curve throughout the entire follow-up, with a mean coefficient of correlation of 0.97±0.01. Conclusions. C2 management of cyclosporine microemulsion therapy is effective and safe in pediatric kidney-transplant recipients given a combined immunosuppressive treatment.

Original languageEnglish
Pages (from-to)1164-1168
Number of pages5
JournalTransplantation
Volume79
Issue number9
DOIs
Publication statusPublished - May 15 2005

Fingerprint

Immunosuppressive Agents
Cyclosporine
Pharmacokinetics
Pediatrics
Kidney
Transplants
Drug Monitoring
Graft Survival
Therapeutics
Glomerular Filtration Rate
Multicenter Studies
Area Under Curve
Creatinine
Serum
Transplant Recipients

Keywords

  • Cyclosporine
  • Pediatric immunosuppression
  • Pediatric kidney transplantation
  • Pharmacokinetic
  • Prospective study

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen : The value of C2 blood levels. / Ferraresso, Mariana; Ghio, Luciana; Zacchello, Graziella; Murer, Luisa; Ginevri, Fabrizio; Perfumo, Francesco; Zanon, Gian Franco; Fontana, Ines; Amore, Alessandro; Edefonti, Alberto; Vigano, Sara; Cardillo, Massimo; Scalamogna, Mario.

In: Transplantation, Vol. 79, No. 9, 15.05.2005, p. 1164-1168.

Research output: Contribution to journalArticle

Ferraresso, M, Ghio, L, Zacchello, G, Murer, L, Ginevri, F, Perfumo, F, Zanon, GF, Fontana, I, Amore, A, Edefonti, A, Vigano, S, Cardillo, M & Scalamogna, M 2005, 'Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen: The value of C2 blood levels', Transplantation, vol. 79, no. 9, pp. 1164-1168. https://doi.org/10.1097/01.TP.0000160762.37225.2B
Ferraresso, Mariana ; Ghio, Luciana ; Zacchello, Graziella ; Murer, Luisa ; Ginevri, Fabrizio ; Perfumo, Francesco ; Zanon, Gian Franco ; Fontana, Ines ; Amore, Alessandro ; Edefonti, Alberto ; Vigano, Sara ; Cardillo, Massimo ; Scalamogna, Mario. / Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen : The value of C2 blood levels. In: Transplantation. 2005 ; Vol. 79, No. 9. pp. 1164-1168.
@article{dd5ce66b59bf4d69a80c89431ded4583,
title = "Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen: The value of C2 blood levels",
abstract = "Background. The management of cyclosporine therapy in pediatric kidney-transplant recipients is largely based on single center's experience rather than on a univocal pharmacokinetic approach based on therapeutic drug monitoring. A prospective multicenter trial was designed to address the question whether C2 blood level monitoring of cyclosporine microemulsion therapy is feasible in the pediatric setting. Methods. Sixty-four pediatric kidney-transplant recipients receiving a triple immunosuppressive regimen based on cyclosporine microemulsion had their cyclosporine dose adjusted to the same protocol-defined C2 targets from the time of the transplant until 2 years posttransplant. The interim analyses after 1 year of enrolment is presented in this study. Results. One-year patient and graft survival were 100{\%} and 94.8{\%}, respectively. One-year rejection rate was 15{\%}. C2 management of cyclosporine did not affect graft function: 1-year serum creatinine and glomerular filtration rate were 1.3±1 mg/mL and 71.2±20 mL/min/1.73 m2, respectively. C2 was the best single-point predictor of the area under the concentration curve throughout the entire follow-up, with a mean coefficient of correlation of 0.97±0.01. Conclusions. C2 management of cyclosporine microemulsion therapy is effective and safe in pediatric kidney-transplant recipients given a combined immunosuppressive treatment.",
keywords = "Cyclosporine, Pediatric immunosuppression, Pediatric kidney transplantation, Pharmacokinetic, Prospective study",
author = "Mariana Ferraresso and Luciana Ghio and Graziella Zacchello and Luisa Murer and Fabrizio Ginevri and Francesco Perfumo and Zanon, {Gian Franco} and Ines Fontana and Alessandro Amore and Alberto Edefonti and Sara Vigano and Massimo Cardillo and Mario Scalamogna",
year = "2005",
month = "5",
day = "15",
doi = "10.1097/01.TP.0000160762.37225.2B",
language = "English",
volume = "79",
pages = "1164--1168",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen

T2 - The value of C2 blood levels

AU - Ferraresso, Mariana

AU - Ghio, Luciana

AU - Zacchello, Graziella

AU - Murer, Luisa

AU - Ginevri, Fabrizio

AU - Perfumo, Francesco

AU - Zanon, Gian Franco

AU - Fontana, Ines

AU - Amore, Alessandro

AU - Edefonti, Alberto

AU - Vigano, Sara

AU - Cardillo, Massimo

AU - Scalamogna, Mario

PY - 2005/5/15

Y1 - 2005/5/15

N2 - Background. The management of cyclosporine therapy in pediatric kidney-transplant recipients is largely based on single center's experience rather than on a univocal pharmacokinetic approach based on therapeutic drug monitoring. A prospective multicenter trial was designed to address the question whether C2 blood level monitoring of cyclosporine microemulsion therapy is feasible in the pediatric setting. Methods. Sixty-four pediatric kidney-transplant recipients receiving a triple immunosuppressive regimen based on cyclosporine microemulsion had their cyclosporine dose adjusted to the same protocol-defined C2 targets from the time of the transplant until 2 years posttransplant. The interim analyses after 1 year of enrolment is presented in this study. Results. One-year patient and graft survival were 100% and 94.8%, respectively. One-year rejection rate was 15%. C2 management of cyclosporine did not affect graft function: 1-year serum creatinine and glomerular filtration rate were 1.3±1 mg/mL and 71.2±20 mL/min/1.73 m2, respectively. C2 was the best single-point predictor of the area under the concentration curve throughout the entire follow-up, with a mean coefficient of correlation of 0.97±0.01. Conclusions. C2 management of cyclosporine microemulsion therapy is effective and safe in pediatric kidney-transplant recipients given a combined immunosuppressive treatment.

AB - Background. The management of cyclosporine therapy in pediatric kidney-transplant recipients is largely based on single center's experience rather than on a univocal pharmacokinetic approach based on therapeutic drug monitoring. A prospective multicenter trial was designed to address the question whether C2 blood level monitoring of cyclosporine microemulsion therapy is feasible in the pediatric setting. Methods. Sixty-four pediatric kidney-transplant recipients receiving a triple immunosuppressive regimen based on cyclosporine microemulsion had their cyclosporine dose adjusted to the same protocol-defined C2 targets from the time of the transplant until 2 years posttransplant. The interim analyses after 1 year of enrolment is presented in this study. Results. One-year patient and graft survival were 100% and 94.8%, respectively. One-year rejection rate was 15%. C2 management of cyclosporine did not affect graft function: 1-year serum creatinine and glomerular filtration rate were 1.3±1 mg/mL and 71.2±20 mL/min/1.73 m2, respectively. C2 was the best single-point predictor of the area under the concentration curve throughout the entire follow-up, with a mean coefficient of correlation of 0.97±0.01. Conclusions. C2 management of cyclosporine microemulsion therapy is effective and safe in pediatric kidney-transplant recipients given a combined immunosuppressive treatment.

KW - Cyclosporine

KW - Pediatric immunosuppression

KW - Pediatric kidney transplantation

KW - Pharmacokinetic

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=20844463787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844463787&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000160762.37225.2B

DO - 10.1097/01.TP.0000160762.37225.2B

M3 - Article

VL - 79

SP - 1164

EP - 1168

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -